SlideShare a Scribd company logo
Adrenaline
Strength 1mg / 1ml
Compatibility NS, D5W.
Dilution 2 mg (2 amp) *50 ml
Concentration
40 mcg/ ml
Dose 0.04–1 mcg/kg/minute
Stability
 24 hr.
 Epinephrine is sensitive to light and air; protection from
light is recommended
Dose (mcg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
0.025 1.1 1.5 1.9 2.3 2.6 3.0 3.4 3.8
0.05 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5
0.075 3.4 4.5 5.6 6.8 7.9 9.0 10.1 11.3
0.1 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0
0.125 5.6 7.5 9.4 11.3 13.1 15.0 16.9 18.8
0.15 6.8 9.0 11.3 13.5 15.8 18.0 20.3 22.5
0.175 7.9 10.5 13.1 15.8 18.4 21.0 23.6 26.3
0.2 9.0 12.0 15.0 18.0 21.0 24.0 27.0 30.0
0.25 11.3 15.0 18.8 22.5 26.3 30.0 33.8 37.5
0.3 13.5 18.0 22.5 27.0 31.5 36.0 40.5 45.0
0.35 15.8 21.0 26.3 31.5 36.8 42.0 47.3 52.5
0.4 18.0 24.0 30.0 36.0 42.0 48.0 54.0 60.0
0.45 20.3 27.0 33.8 40.5 47.3 54.0 60.8 67.5
0.5 22.5 30.0 37.5 45.0 52.5 60.0 67.5 75.0
Noradrenaline
Strength 4mg / 4ml
Compatibility D5W.
Dilution 4 mg (1 amp) * 50 ml
Concentration
80 mcg/ ml
Dose 0.01–3 mcg/kg/minute
Stability
 24 hr.
 keep away from light ,don’t use if brown coloration
(oxidized),
Dose (mcg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
0.025 1.1 1.5 1.9 2.3 2.6 3.0 3.4 3.8
0.05 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5
0.075 3.4 4.5 5.6 6.8 7.9 9.0 10.1 11.3
0.1 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0
0.125 5.6 7.5 9.4 11.3 13.1 15.0 16.9 18.8
0.15 6.8 9.0 11.3 13.5 15.8 18.0 20.3 22.5
0.175 7.9 10.5 13.1 15.8 18.4 21.0 23.6 26.3
0.2 9.0 12.0 15.0 18.0 21.0 24.0 27.0 30.0
0.25 11.3 15.0 18.8 22.5 26.3 30.0 33.8 37.5
0.3 13.5 18.0 22.5 27.0 31.5 36.0 40.5 45.0
0.35 15.8 21.0 26.3 31.5 36.8 42.0 47.3 52.5
0.4 18.0 24.0 30.0 36.0 42.0 48.0 54.0 60.0
0.45 20.3 27.0 33.8 40.5 47.3 54.0 60.8 67.5
0.5 22.5 30.0 37.5 45.0 52.5 60.0 67.5 75.0
Dobutamine
Strength 250 mg / 20 ml
Compatibility D5W, NS
Dilution 250 mg (1 amp) *50 ml
Concentration
5000 mcg/ ml
Dose
2–20 mcg/kg/minute
 Some literature state that maximum dose is 40mcg/kg/min
 But ACC/AHA recommend maximum dose of 20mcg/kg/min
Stability  24 hr.
Dose (mcg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
5 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0
6 2.2 2.9 3.6 4.3 5.0 5.8 6.5 7.2
7 2.5 3.4 4.2 5.0 5.9 6.7 7.6 8.4
8 2.9 3.8 4.8 5.8 6.7 7.7 8.6 9.6
9 3.2 4.3 5.4 6.5 7.6 8.6 9.7 10.8
10 3.6 4.8 6.0 7.2 8.4 9.6 10.8 12.0
11 4.0 5.3 6.6 7.9 9.2 10.6 11.9 13.2
12 4.3 5.8 7.2 8.6 10.1 11.5 13.0 14.4
13 4.7 6.2 7.8 9.4 10.9 12.5 14.0 15.6
14 5.0 6.7 8.4 10.1 11.8 13.4 15.1 16.8
15 5.4 7.2 9.0 10.8 12.6 14.4 16.2 18.0
16 5.8 7.7 9.6 11.5 13.4 15.4 17.3 19.2
17 6.1 8.2 10.2 12.2 14.3 16.3 18.4 20.4
18 6.5 8.6 10.8 13.0 15.1 17.3 19.4 21.6
19 6.8 9.1 11.4 13.7 16.0 18.2 20.5 22.8
20 7.2 9.6 12.0 14.4 16.8 19.2 21.6 24.0
Dopamine
Strength 200 mg / 5 ml
Compatibility D5W, NS
Dilution 200 mg (1 amp) *50 ml
Concentration
4000 mcg/ ml
Dose
Dopa dose 1-3mcg/kg/min (evidence does not support this practice)
Beta dose 4- 10mcg/kg/min
Alpha dose >10mcg/kg/min (above 20 mcg/kg/min not recommended)
Stability  24 hr.
Dose (mcg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
1 0.5 0.6 0.8 0.9 1.1 1.2 1.4 1.5
2 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3.0
3 1.4 1.8 2.3 2.7 3.2 3.6 4.1 4.5
4 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0
5 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5
7.5 3.4 4.5 5.6 6.8 7.9 9.0 10.1 11.3
10 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0
12.5 5.6 7.5 9.4 11.3 13.1 15.0 16.9 18.8
15 6.8 9.0 11.3 13.5 15.8 18.0 20.3 22.5
17.5 7.9 10.5 13.1 15.8 18.4 21.0 23.6 26.3
20 9.0 12.0 15.0 18.0 21.0 24.0 27.0 30.0
Nitrogylcerine
Strength 50 mg / 10 ml
Compatibility D5W
Dilution 10 mg (2 ml) *50 ml
Concentration 200 mcg/ ml
Dose
5- 200 mcg/minute
(increase by 5 mcg/minute every 5 min)
Stability  24 hr.
Dose
(mcg/min)
Infusion Rates
(ml/ hr)
Dose
(mcg/min)
Infusion Rates
(ml/ hr)
5 1.5 100 30
10 3 110 33
15 4.5 120 36
20 6 130 39
30 9 140 42
40 12 150 45
50 15 160 48
60 18 170 51
70 21 180 54
80 24 190 57
90 27 200 60
Nitroprusside
Strength 50 mg / 2 ml
Compatibility D5W
Dilution 50 mg( 1 amp) *250 ml
Concentration 200 mcg/ ml
Dose
0.2 - 10 mcg/kg/minute
Doses >5 mcg/kg/minute are not recommended
Stability
 24 hr.
 Prepare it away from light
 wrapped immediately with aluminum foil
Dose (mcg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
0.1 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3
0.2 1.8 2.4 3 3.6 4.2 4.8 5.4 6
0.3 2.7 3.6 4.5 5.4 6.3 7.2 8.1 9
0.4 3.6 4.8 6 7.2 8.4 9.6 10.8 12
0.5 4.5 6 7.5 9 10.5 12 13.5 15
1 9 12 15 18 21 24 27 30
2 18 24 30 36 42 48 54 60
3 27 36 45 54 63 72 81 90
4 36 48 60 72 84 96 108 120
5 45 60 75 90 105 120 135 150
6 54 72 90 108 126 144 162 180
7 63 84 105 126 147 168 189 210
8 72 96 120 144 168 192 216 240
9 81 108 135 162 189 216 243 270
10 90 120 150 180 210 240 270 300
Heparin
Strength 5000 IU /amp
Compatibility NS
Dilution 25000 IU ( 5 amp) *50 ml
Concentration 500 IU / ml
Dose 80 units/kg then 18 units/kg/hour
Stability
 24 hr.
 Prepare it away from light
 wrapped immediately with aluminum foil
Dose (IU) WT(kg) 30 40 50 60 70 80 90 100
Loading (80
units/kg)
2400
IU
3200
IU
4000
IU
4800
IU
5600
IU
6400
IU
7200
IU
8000
IU
Maintenance
(18 units/kg/hour)
Infusion Rates ml/ hr
0.768 1.024 1.28 1.536 1.792 2.048 2.304 2.56
Fentanyl
Strength 50 mcg/ml amp=2ml
Compatibility D5W, NS.
Dilution 500 mcg (5 amp) *50 ml
Concentration 10 mcg / ml
Dose 0.5 to 10 mcg/kg/hr IV
Stability  24 hr
Dose (mcg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
0.5 1.5 2 2.5 3 3.5 4 4.5 5
0.75 2.25 3 3.75 4.5 5.25 6 6.75 7.5
1 3 4 5 6 7 8 9 10
1.25 3.75 5 6.25 7.5 8.75 10 11.25 12.5
1.5 4.5 6 7.5 9 10.5 12 13.5 15
1.75 5.25 7 8.75 10.5 12.25 14 15.75 17.5
2 6 8 10 12 14 16 18 20
2.25 6.75 9 11.25 13.5 15.75 18 20.25 22.5
2.5 7.5 10 12.5 15 17.5 20 22.5 25
3 9 12 15 18 21 24 27 30
3.5 10.5 14 17.5 21 24.5 28 31.5 35
4 12 16 20 24 28 32 36 40
4.5 13.5 18 22.5 27 31.5 36 40.5 45
5 15 20 25 30 35 40 45 50
Midazolam
Strength 5 mg/ml amp=3ml
Compatibility D5W, NS. Incompatible with LR.
Dilution 45 mg (3 amp) *45 ml
Concentration 1 mg / ml
Dose
Initial dose (0.01 – 0.05 mg/kg) OR 0.5 to 4 mg
Maintenance infusion: 0.02 to 0.1 mg/kg/hour
Stability  24 hr
Dose (mg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
0.02 0.6 0.8 1 1.2 1.4 1.6 1.8 2
0.03 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3
0.04 1.2 1.6 2 2.4 2.8 3.2 3.6 4
0.05 1.5 2 2.5 3 3.5 4 4.5 5
0.06 1.8 2.4 3 3.6 4.2 4.8 5.4 6
0.07 2.1 2.8 3.5 4.2 4.9 5.6 6.3 7
0.08 2.4 3.2 4 4.8 5.6 6.4 7.2 8
0.09 2.7 3.6 4.5 5.4 6.3 7.2 8.1 9
0.1 3 4 5 6 7 8 9 10
Propofol
Strength 10 mg/ml (1%) amp=20ml
Compatibility Does not need to be diluted
Dilution 500 mg (2.5 amp) Total 50 ml
Concentration 10 mg / ml
Dose
 Initial dose (0.3 mg/kg)
 Maintenance infusion: 0.3 to 3 mg/kg/hour
Stability
 If transferred to a syringe or other container prior to
administration, use within 6 hours.
 If diluted in 5% dextrose stable for 8 hours at room
temperature
Dose (mg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
0.3 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3
0.4 1.2 1.6 2 2.4 2.8 3.2 3.6 4
0.5 1.5 2 2.5 3 3.5 4 4.5 5
0.75 2.25 3 3.75 4.5 5.25 6 6.75 7.5
1 3 4 5 6 7 8 9 10
1.25 3.75 5 6.25 7.5 8.75 10 11.25 12.5
1.5 4.5 6 7.5 9 10.5 12 13.5 15
1.75 5.25 7 8.75 10.5 12.25 14 15.75 17.5
2 6 8 10 12 14 16 18 20
2.25 6.75 9 11.25 13.5 15.75 18 20.25 22.5
2.5 7.5 10 12.5 15 17.5 20 22.5 25
2.75 8.25 11 13.75 16.5 19.25 22 24.75 27.5
3 9 12 15 18 21 24 27 30
Insulin Infusion Protocol
1. Standard infusion: 50 Units Regular insulin/50 mL NS via an infusion device
2. For most patients, the goal BG should be between 90-140 mg/dL.
3. Initiating the Infusion:
 Algorithm 1: Start here for most patients.
 Algorithm 2: Start here if the patient has a glucose > 600 mg/dL, is in diabetic ketoacidosis, or
is s/p CABG, s/p solid organ transplant, receiving glucocorticoids, or patient with diabetes
receiving over 80 units/day of insulin as an outpatient, has a BMI more then 35, or is pregnant.
 Algorithms 3-8: Do not start patients in these algorithms.
4. Patient Monitoring:
 Hourly monitoring is indicated for most critically ill patients.
 For stable patients, check BG every hour until it is within goal range (90 – 140 mg/dL) for 4
hours, then decrease BG checks to every 2 hours.
6. Moving down from Algorithm to Algorithm When glucose decreases >60 mg/dl in 1 hour
Blood Glucose Adjustment
BG < 60 mg/dL Treatment of Hypoglycemia
BG 61-90 mg/dL Turn off the infusion and recheck BG every 1 hour
until> 90 mg/dL and then restart infusion in next
Lower algorithm
BG between 90 and 140 mg/dL (goal) Adjust the rate within the SAME algorithm
BG between 141 and 180 mg/dL and decreased by
30 mg/dL or more
Adjust the rate within the SAME algorithm
BG between 141 and 180 mg/dL and did not
decrease by at least 30 mg/dL
Adjust the rate to the next HIGHER algorithm
BG > 180 mg/dL and decreased by 60 mg/dL or
more
Adjust the rate within the SAME algorithm
BG > 180 mg/dL and did not decrease by at least 60
mg/dL
Adjust the rate to the next HIGHER algorithm
Blood Glucose
(mg/dl)
Scale 1
(ml/hr)
Scale 2
(ml/hr)
Scale 3
(ml/hr)
Scale 4
(ml/hr)
Scale 5
(ml/hr)
Scale 6
(ml/hr)
Scale 7
(ml/hr)
Scale 8
(ml/hr)
≥400 3 4 5 6 7 8 10 11
320-399 2.5 3.5 4 5 6 6 8 9
250-319 2 3 3 4 5 5 6 7
210-249 1.5 2.5 2.5 3 4 4 4 5
180-209 1 2 2 2 3 3 3 4
140-179 1 1.5 1.5 1.5 2 2 2.5 3
110-139 0.5 1 1 1 1.5 1.5 2 2
90-109 0.5 0.5 0.5 1 1 1 1.5 1.5
<90 Stop IV insulin infusion and inform doctor
Rocuronium Bromide (Esmeron)
Strength 10 mg/ml amp=5ml
Compatibility D5W, NS.
Dilution 250 mg (5 amp) *50 ml
Concentration 5 mg / ml
Dose
Initial dose (0.6 mg/kg)
Maintenance infusion: 0.3 to 0.6 mg/kg/hour
Stability  24 hr
Dose (mg) WT(kg)
30 40 50 60 70 80 90 100
Infusion Rates ml/ hr
0.3 1.8 2.4 3 3.6 4.2 4.8 5.4 6
0.35 2.1 2.8 3.5 4.2 4.9 5.6 6.3 7
0.4 2.4 3.2 4 4.8 5.6 6.4 7.2 8
0.45 2.7 3.6 4.5 5.4 6.3 7.2 8.1 9
0.5 3 4 5 6 7 8 9 10
0.55 3.3 4.4 5.5 6.6 7.7 8.8 9.9 11
0.6 3.6 4.8 6 7.2 8.4 9.6 10.8 12

More Related Content

What's hot

Pulmonary artery catheter
Pulmonary artery catheterPulmonary artery catheter
Pulmonary artery catheter
rajkumarsrihari
 
INTRA-ARTERIAL BLOOD PRESSURE MONITORING
INTRA-ARTERIAL BLOOD PRESSURE MONITORING INTRA-ARTERIAL BLOOD PRESSURE MONITORING
INTRA-ARTERIAL BLOOD PRESSURE MONITORING
vikramnaidu2311
 
Cardiac arrest
Cardiac arrestCardiac arrest
Cardiac arrest
Doha Rasheedy
 
Arterial lines by Dr.Tinku Joseph
Arterial lines by Dr.Tinku JosephArterial lines by Dr.Tinku Joseph
Arterial lines by Dr.Tinku Joseph
Dr.Tinku Joseph
 
Inotropes and vasopressors
Inotropes and vasopressorsInotropes and vasopressors
Inotropes and vasopressors
pankaj rana
 
Nor adrenalin
Nor adrenalinNor adrenalin
Nor adrenalin
Johny Wilbert
 
Sodium Bicarbonate Revisited
Sodium Bicarbonate RevisitedSodium Bicarbonate Revisited
Sodium Bicarbonate Revisited
Creativity Please
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choice
Dharmraj Singh
 
Ventilator associated pneumonia VAP
Ventilator associated pneumonia VAPVentilator associated pneumonia VAP
Ventilator associated pneumonia VAP
Abdelrahman Al-daqqa
 
Ventilator mode
Ventilator modeVentilator mode
Ventilator mode
Shoaib Kashem
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1
MEEQAT HOSPITAL
 
Vasopressors
VasopressorsVasopressors
Vasopressors
Aftab Hussain
 
Sodium correction formula
Sodium correction formulaSodium correction formula
Sodium correction formula
Dr. Ravikiran H M Gowda
 
Amiodarone
AmiodaroneAmiodarone
Amiodarone
Quang Huy Phạm
 
Cardiac risk stratification
Cardiac risk stratificationCardiac risk stratification
Cardiac risk stratification
Dr.S.N.Bhagirath ..
 
Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome
Lavina Belayutham
 
Inotropes & vasoactive agents
Inotropes & vasoactive agentsInotropes & vasoactive agents
Inotropes & vasoactive agents
Manoj Prabhakar
 
Pulmonary artery pressure monitoring
Pulmonary artery pressure monitoringPulmonary artery pressure monitoring
Pulmonary artery pressure monitoring
Princy Francis M
 
Approach to bradycardia
Approach to bradycardiaApproach to bradycardia
Approach to bradycardia
Faez Toushiro
 

What's hot (20)

Pulmonary artery catheter
Pulmonary artery catheterPulmonary artery catheter
Pulmonary artery catheter
 
INTRA-ARTERIAL BLOOD PRESSURE MONITORING
INTRA-ARTERIAL BLOOD PRESSURE MONITORING INTRA-ARTERIAL BLOOD PRESSURE MONITORING
INTRA-ARTERIAL BLOOD PRESSURE MONITORING
 
Cardiac arrest
Cardiac arrestCardiac arrest
Cardiac arrest
 
Arterial lines by Dr.Tinku Joseph
Arterial lines by Dr.Tinku JosephArterial lines by Dr.Tinku Joseph
Arterial lines by Dr.Tinku Joseph
 
Inotropes and vasopressors
Inotropes and vasopressorsInotropes and vasopressors
Inotropes and vasopressors
 
Nor adrenalin
Nor adrenalinNor adrenalin
Nor adrenalin
 
Sodium Bicarbonate Revisited
Sodium Bicarbonate RevisitedSodium Bicarbonate Revisited
Sodium Bicarbonate Revisited
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choice
 
Ventilator associated pneumonia VAP
Ventilator associated pneumonia VAPVentilator associated pneumonia VAP
Ventilator associated pneumonia VAP
 
Ventilator mode
Ventilator modeVentilator mode
Ventilator mode
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1
 
Vasopressors
VasopressorsVasopressors
Vasopressors
 
Sodium correction formula
Sodium correction formulaSodium correction formula
Sodium correction formula
 
Amiodarone
AmiodaroneAmiodarone
Amiodarone
 
Cardiac risk stratification
Cardiac risk stratificationCardiac risk stratification
Cardiac risk stratification
 
Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome
 
Extubation
Extubation Extubation
Extubation
 
Inotropes & vasoactive agents
Inotropes & vasoactive agentsInotropes & vasoactive agents
Inotropes & vasoactive agents
 
Pulmonary artery pressure monitoring
Pulmonary artery pressure monitoringPulmonary artery pressure monitoring
Pulmonary artery pressure monitoring
 
Approach to bradycardia
Approach to bradycardiaApproach to bradycardia
Approach to bradycardia
 

Similar to Critical care drug infusion

Pediatric Emergency & Medications Doses By Dr Essam Sidqi
Pediatric Emergency & Medications Doses By Dr Essam SidqiPediatric Emergency & Medications Doses By Dr Essam Sidqi
Pediatric Emergency & Medications Doses By Dr Essam Sidqi
Essam Sidqi Yaqoob
 
Contoh 2 TPN
Contoh 2 TPNContoh 2 TPN
Contoh 2 TPN
Anisya Al Husna
 
PediRefCard.pdf
PediRefCard.pdfPediRefCard.pdf
PediRefCard.pdf
MuhammadAbbasWali
 
NNF ready reckoner.pdf
NNF ready reckoner.pdfNNF ready reckoner.pdf
NNF ready reckoner.pdf
KickKick6
 
Optimization parameters in Countercurrent Chromatography
Optimization parameters in Countercurrent ChromatographyOptimization parameters in Countercurrent Chromatography
Optimization parameters in Countercurrent Chromatography
Center for Natural Product Technologies
 
Formulation and evaluation of sitagliptan floating tablets
Formulation and evaluation of sitagliptan floating tabletsFormulation and evaluation of sitagliptan floating tablets
Formulation and evaluation of sitagliptan floating tablets
SriramNagarajan19
 
Intravenous Drug Preparation and Administration EMTS Johore (1).pdf
Intravenous Drug Preparation and Administration  EMTS Johore (1).pdfIntravenous Drug Preparation and Administration  EMTS Johore (1).pdf
Intravenous Drug Preparation and Administration EMTS Johore (1).pdf
azhaabaz
 
ECMO trong quản lý sốc tim
ECMO trong quản lý sốc timECMO trong quản lý sốc tim
ECMO trong quản lý sốc tim
SoM
 
cardiologische topics huisartsen
cardiologische topics huisartsencardiologische topics huisartsen
cardiologische topics huisartsen
guyodent
 
Drugs
DrugsDrugs
Febuxostat for treatment of chronic gout
Febuxostat for treatment of chronic goutFebuxostat for treatment of chronic gout
Febuxostat for treatment of chronic goutChoying Chen
 
Antibiotics Pediatric dosing.pdf
Antibiotics Pediatric dosing.pdfAntibiotics Pediatric dosing.pdf
Antibiotics Pediatric dosing.pdf
Rahul Verma
 
List of validated methods 030915
List of validated methods 030915List of validated methods 030915
List of validated methods 030915Sitec Labs
 
Pediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdf
Pediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdfPediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdf
Pediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdf
Essam Sidqi Yaqoob
 
3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf
3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf
3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf
Essam Sidqi Yaqoob
 
critical values
 critical values critical values
critical values
jouzi
 
Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...
Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...
Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...
Waters Corporation
 
dosis anak test.docx
dosis anak test.docxdosis anak test.docx
dosis anak test.docx
Tiwa Ramadan
 
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdfBASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
najmishafiz
 

Similar to Critical care drug infusion (20)

Pediatric Emergency & Medications Doses By Dr Essam Sidqi
Pediatric Emergency & Medications Doses By Dr Essam SidqiPediatric Emergency & Medications Doses By Dr Essam Sidqi
Pediatric Emergency & Medications Doses By Dr Essam Sidqi
 
Contoh 2 TPN
Contoh 2 TPNContoh 2 TPN
Contoh 2 TPN
 
PediRefCard.pdf
PediRefCard.pdfPediRefCard.pdf
PediRefCard.pdf
 
NNF ready reckoner.pdf
NNF ready reckoner.pdfNNF ready reckoner.pdf
NNF ready reckoner.pdf
 
Optimization parameters in Countercurrent Chromatography
Optimization parameters in Countercurrent ChromatographyOptimization parameters in Countercurrent Chromatography
Optimization parameters in Countercurrent Chromatography
 
Formulation and evaluation of sitagliptan floating tablets
Formulation and evaluation of sitagliptan floating tabletsFormulation and evaluation of sitagliptan floating tablets
Formulation and evaluation of sitagliptan floating tablets
 
Intravenous Drug Preparation and Administration EMTS Johore (1).pdf
Intravenous Drug Preparation and Administration  EMTS Johore (1).pdfIntravenous Drug Preparation and Administration  EMTS Johore (1).pdf
Intravenous Drug Preparation and Administration EMTS Johore (1).pdf
 
ECMO trong quản lý sốc tim
ECMO trong quản lý sốc timECMO trong quản lý sốc tim
ECMO trong quản lý sốc tim
 
cardiologische topics huisartsen
cardiologische topics huisartsencardiologische topics huisartsen
cardiologische topics huisartsen
 
Drugs
DrugsDrugs
Drugs
 
Febuxostat for treatment of chronic gout
Febuxostat for treatment of chronic goutFebuxostat for treatment of chronic gout
Febuxostat for treatment of chronic gout
 
Antibiotics Pediatric dosing.pdf
Antibiotics Pediatric dosing.pdfAntibiotics Pediatric dosing.pdf
Antibiotics Pediatric dosing.pdf
 
List of validated methods 030915
List of validated methods 030915List of validated methods 030915
List of validated methods 030915
 
The Use of Ultra-Short Opiods in Anesthesia
The Use of Ultra-Short Opiods in AnesthesiaThe Use of Ultra-Short Opiods in Anesthesia
The Use of Ultra-Short Opiods in Anesthesia
 
Pediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdf
Pediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdfPediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdf
Pediatrics Emergency And Medications Doses By Dr Essam Sidqi 2e.pdf
 
3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf
3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf
3rd Edition Pediatrics Emergency And Medications Doses By Dr Essam Sidqi.pdf
 
critical values
 critical values critical values
critical values
 
Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...
Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...
Comprehensive Investigation of the Utilization of SFC/ESI Positive Mode MS fo...
 
dosis anak test.docx
dosis anak test.docxdosis anak test.docx
dosis anak test.docx
 
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdfBASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
 

More from Ali Mahareak

ICU Protocols
ICU ProtocolsICU Protocols
ICU Protocols
Ali Mahareak
 
ANESTHESIA FOR CONGENITAL HEART DISEASES
ANESTHESIA FOR CONGENITAL HEART DISEASES ANESTHESIA FOR CONGENITAL HEART DISEASES
ANESTHESIA FOR CONGENITAL HEART DISEASES
Ali Mahareak
 
Chest US mahareak
Chest US  mahareakChest US  mahareak
Chest US mahareak
Ali Mahareak
 
Spss mahareak
Spss mahareakSpss mahareak
Spss mahareak
Ali Mahareak
 
Mahareak myasthenia
Mahareak  myastheniaMahareak  myasthenia
Mahareak myasthenia
Ali Mahareak
 
Stents mahareak
Stents mahareakStents mahareak
Stents mahareak
Ali Mahareak
 

More from Ali Mahareak (6)

ICU Protocols
ICU ProtocolsICU Protocols
ICU Protocols
 
ANESTHESIA FOR CONGENITAL HEART DISEASES
ANESTHESIA FOR CONGENITAL HEART DISEASES ANESTHESIA FOR CONGENITAL HEART DISEASES
ANESTHESIA FOR CONGENITAL HEART DISEASES
 
Chest US mahareak
Chest US  mahareakChest US  mahareak
Chest US mahareak
 
Spss mahareak
Spss mahareakSpss mahareak
Spss mahareak
 
Mahareak myasthenia
Mahareak  myastheniaMahareak  myasthenia
Mahareak myasthenia
 
Stents mahareak
Stents mahareakStents mahareak
Stents mahareak
 

Recently uploaded

Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 

Recently uploaded (20)

Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 

Critical care drug infusion

  • 1. Adrenaline Strength 1mg / 1ml Compatibility NS, D5W. Dilution 2 mg (2 amp) *50 ml Concentration 40 mcg/ ml Dose 0.04–1 mcg/kg/minute Stability  24 hr.  Epinephrine is sensitive to light and air; protection from light is recommended Dose (mcg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 0.025 1.1 1.5 1.9 2.3 2.6 3.0 3.4 3.8 0.05 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 0.075 3.4 4.5 5.6 6.8 7.9 9.0 10.1 11.3 0.1 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0 0.125 5.6 7.5 9.4 11.3 13.1 15.0 16.9 18.8 0.15 6.8 9.0 11.3 13.5 15.8 18.0 20.3 22.5 0.175 7.9 10.5 13.1 15.8 18.4 21.0 23.6 26.3 0.2 9.0 12.0 15.0 18.0 21.0 24.0 27.0 30.0 0.25 11.3 15.0 18.8 22.5 26.3 30.0 33.8 37.5 0.3 13.5 18.0 22.5 27.0 31.5 36.0 40.5 45.0 0.35 15.8 21.0 26.3 31.5 36.8 42.0 47.3 52.5 0.4 18.0 24.0 30.0 36.0 42.0 48.0 54.0 60.0 0.45 20.3 27.0 33.8 40.5 47.3 54.0 60.8 67.5 0.5 22.5 30.0 37.5 45.0 52.5 60.0 67.5 75.0
  • 2. Noradrenaline Strength 4mg / 4ml Compatibility D5W. Dilution 4 mg (1 amp) * 50 ml Concentration 80 mcg/ ml Dose 0.01–3 mcg/kg/minute Stability  24 hr.  keep away from light ,don’t use if brown coloration (oxidized), Dose (mcg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 0.025 1.1 1.5 1.9 2.3 2.6 3.0 3.4 3.8 0.05 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 0.075 3.4 4.5 5.6 6.8 7.9 9.0 10.1 11.3 0.1 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0 0.125 5.6 7.5 9.4 11.3 13.1 15.0 16.9 18.8 0.15 6.8 9.0 11.3 13.5 15.8 18.0 20.3 22.5 0.175 7.9 10.5 13.1 15.8 18.4 21.0 23.6 26.3 0.2 9.0 12.0 15.0 18.0 21.0 24.0 27.0 30.0 0.25 11.3 15.0 18.8 22.5 26.3 30.0 33.8 37.5 0.3 13.5 18.0 22.5 27.0 31.5 36.0 40.5 45.0 0.35 15.8 21.0 26.3 31.5 36.8 42.0 47.3 52.5 0.4 18.0 24.0 30.0 36.0 42.0 48.0 54.0 60.0 0.45 20.3 27.0 33.8 40.5 47.3 54.0 60.8 67.5 0.5 22.5 30.0 37.5 45.0 52.5 60.0 67.5 75.0
  • 3. Dobutamine Strength 250 mg / 20 ml Compatibility D5W, NS Dilution 250 mg (1 amp) *50 ml Concentration 5000 mcg/ ml Dose 2–20 mcg/kg/minute  Some literature state that maximum dose is 40mcg/kg/min  But ACC/AHA recommend maximum dose of 20mcg/kg/min Stability  24 hr. Dose (mcg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 5 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 6 2.2 2.9 3.6 4.3 5.0 5.8 6.5 7.2 7 2.5 3.4 4.2 5.0 5.9 6.7 7.6 8.4 8 2.9 3.8 4.8 5.8 6.7 7.7 8.6 9.6 9 3.2 4.3 5.4 6.5 7.6 8.6 9.7 10.8 10 3.6 4.8 6.0 7.2 8.4 9.6 10.8 12.0 11 4.0 5.3 6.6 7.9 9.2 10.6 11.9 13.2 12 4.3 5.8 7.2 8.6 10.1 11.5 13.0 14.4 13 4.7 6.2 7.8 9.4 10.9 12.5 14.0 15.6 14 5.0 6.7 8.4 10.1 11.8 13.4 15.1 16.8 15 5.4 7.2 9.0 10.8 12.6 14.4 16.2 18.0 16 5.8 7.7 9.6 11.5 13.4 15.4 17.3 19.2 17 6.1 8.2 10.2 12.2 14.3 16.3 18.4 20.4 18 6.5 8.6 10.8 13.0 15.1 17.3 19.4 21.6 19 6.8 9.1 11.4 13.7 16.0 18.2 20.5 22.8 20 7.2 9.6 12.0 14.4 16.8 19.2 21.6 24.0
  • 4. Dopamine Strength 200 mg / 5 ml Compatibility D5W, NS Dilution 200 mg (1 amp) *50 ml Concentration 4000 mcg/ ml Dose Dopa dose 1-3mcg/kg/min (evidence does not support this practice) Beta dose 4- 10mcg/kg/min Alpha dose >10mcg/kg/min (above 20 mcg/kg/min not recommended) Stability  24 hr. Dose (mcg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 1 0.5 0.6 0.8 0.9 1.1 1.2 1.4 1.5 2 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3.0 3 1.4 1.8 2.3 2.7 3.2 3.6 4.1 4.5 4 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 5 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 7.5 3.4 4.5 5.6 6.8 7.9 9.0 10.1 11.3 10 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0 12.5 5.6 7.5 9.4 11.3 13.1 15.0 16.9 18.8 15 6.8 9.0 11.3 13.5 15.8 18.0 20.3 22.5 17.5 7.9 10.5 13.1 15.8 18.4 21.0 23.6 26.3 20 9.0 12.0 15.0 18.0 21.0 24.0 27.0 30.0
  • 5. Nitrogylcerine Strength 50 mg / 10 ml Compatibility D5W Dilution 10 mg (2 ml) *50 ml Concentration 200 mcg/ ml Dose 5- 200 mcg/minute (increase by 5 mcg/minute every 5 min) Stability  24 hr. Dose (mcg/min) Infusion Rates (ml/ hr) Dose (mcg/min) Infusion Rates (ml/ hr) 5 1.5 100 30 10 3 110 33 15 4.5 120 36 20 6 130 39 30 9 140 42 40 12 150 45 50 15 160 48 60 18 170 51 70 21 180 54 80 24 190 57 90 27 200 60
  • 6. Nitroprusside Strength 50 mg / 2 ml Compatibility D5W Dilution 50 mg( 1 amp) *250 ml Concentration 200 mcg/ ml Dose 0.2 - 10 mcg/kg/minute Doses >5 mcg/kg/minute are not recommended Stability  24 hr.  Prepare it away from light  wrapped immediately with aluminum foil Dose (mcg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 0.1 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3 0.2 1.8 2.4 3 3.6 4.2 4.8 5.4 6 0.3 2.7 3.6 4.5 5.4 6.3 7.2 8.1 9 0.4 3.6 4.8 6 7.2 8.4 9.6 10.8 12 0.5 4.5 6 7.5 9 10.5 12 13.5 15 1 9 12 15 18 21 24 27 30 2 18 24 30 36 42 48 54 60 3 27 36 45 54 63 72 81 90 4 36 48 60 72 84 96 108 120 5 45 60 75 90 105 120 135 150 6 54 72 90 108 126 144 162 180 7 63 84 105 126 147 168 189 210 8 72 96 120 144 168 192 216 240 9 81 108 135 162 189 216 243 270 10 90 120 150 180 210 240 270 300
  • 7. Heparin Strength 5000 IU /amp Compatibility NS Dilution 25000 IU ( 5 amp) *50 ml Concentration 500 IU / ml Dose 80 units/kg then 18 units/kg/hour Stability  24 hr.  Prepare it away from light  wrapped immediately with aluminum foil Dose (IU) WT(kg) 30 40 50 60 70 80 90 100 Loading (80 units/kg) 2400 IU 3200 IU 4000 IU 4800 IU 5600 IU 6400 IU 7200 IU 8000 IU Maintenance (18 units/kg/hour) Infusion Rates ml/ hr 0.768 1.024 1.28 1.536 1.792 2.048 2.304 2.56
  • 8. Fentanyl Strength 50 mcg/ml amp=2ml Compatibility D5W, NS. Dilution 500 mcg (5 amp) *50 ml Concentration 10 mcg / ml Dose 0.5 to 10 mcg/kg/hr IV Stability  24 hr Dose (mcg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 0.5 1.5 2 2.5 3 3.5 4 4.5 5 0.75 2.25 3 3.75 4.5 5.25 6 6.75 7.5 1 3 4 5 6 7 8 9 10 1.25 3.75 5 6.25 7.5 8.75 10 11.25 12.5 1.5 4.5 6 7.5 9 10.5 12 13.5 15 1.75 5.25 7 8.75 10.5 12.25 14 15.75 17.5 2 6 8 10 12 14 16 18 20 2.25 6.75 9 11.25 13.5 15.75 18 20.25 22.5 2.5 7.5 10 12.5 15 17.5 20 22.5 25 3 9 12 15 18 21 24 27 30 3.5 10.5 14 17.5 21 24.5 28 31.5 35 4 12 16 20 24 28 32 36 40 4.5 13.5 18 22.5 27 31.5 36 40.5 45 5 15 20 25 30 35 40 45 50
  • 9. Midazolam Strength 5 mg/ml amp=3ml Compatibility D5W, NS. Incompatible with LR. Dilution 45 mg (3 amp) *45 ml Concentration 1 mg / ml Dose Initial dose (0.01 – 0.05 mg/kg) OR 0.5 to 4 mg Maintenance infusion: 0.02 to 0.1 mg/kg/hour Stability  24 hr Dose (mg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 0.02 0.6 0.8 1 1.2 1.4 1.6 1.8 2 0.03 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3 0.04 1.2 1.6 2 2.4 2.8 3.2 3.6 4 0.05 1.5 2 2.5 3 3.5 4 4.5 5 0.06 1.8 2.4 3 3.6 4.2 4.8 5.4 6 0.07 2.1 2.8 3.5 4.2 4.9 5.6 6.3 7 0.08 2.4 3.2 4 4.8 5.6 6.4 7.2 8 0.09 2.7 3.6 4.5 5.4 6.3 7.2 8.1 9 0.1 3 4 5 6 7 8 9 10
  • 10. Propofol Strength 10 mg/ml (1%) amp=20ml Compatibility Does not need to be diluted Dilution 500 mg (2.5 amp) Total 50 ml Concentration 10 mg / ml Dose  Initial dose (0.3 mg/kg)  Maintenance infusion: 0.3 to 3 mg/kg/hour Stability  If transferred to a syringe or other container prior to administration, use within 6 hours.  If diluted in 5% dextrose stable for 8 hours at room temperature Dose (mg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 0.3 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3 0.4 1.2 1.6 2 2.4 2.8 3.2 3.6 4 0.5 1.5 2 2.5 3 3.5 4 4.5 5 0.75 2.25 3 3.75 4.5 5.25 6 6.75 7.5 1 3 4 5 6 7 8 9 10 1.25 3.75 5 6.25 7.5 8.75 10 11.25 12.5 1.5 4.5 6 7.5 9 10.5 12 13.5 15 1.75 5.25 7 8.75 10.5 12.25 14 15.75 17.5 2 6 8 10 12 14 16 18 20 2.25 6.75 9 11.25 13.5 15.75 18 20.25 22.5 2.5 7.5 10 12.5 15 17.5 20 22.5 25 2.75 8.25 11 13.75 16.5 19.25 22 24.75 27.5 3 9 12 15 18 21 24 27 30
  • 11. Insulin Infusion Protocol 1. Standard infusion: 50 Units Regular insulin/50 mL NS via an infusion device 2. For most patients, the goal BG should be between 90-140 mg/dL. 3. Initiating the Infusion:  Algorithm 1: Start here for most patients.  Algorithm 2: Start here if the patient has a glucose > 600 mg/dL, is in diabetic ketoacidosis, or is s/p CABG, s/p solid organ transplant, receiving glucocorticoids, or patient with diabetes receiving over 80 units/day of insulin as an outpatient, has a BMI more then 35, or is pregnant.  Algorithms 3-8: Do not start patients in these algorithms. 4. Patient Monitoring:  Hourly monitoring is indicated for most critically ill patients.  For stable patients, check BG every hour until it is within goal range (90 – 140 mg/dL) for 4 hours, then decrease BG checks to every 2 hours. 6. Moving down from Algorithm to Algorithm When glucose decreases >60 mg/dl in 1 hour Blood Glucose Adjustment BG < 60 mg/dL Treatment of Hypoglycemia BG 61-90 mg/dL Turn off the infusion and recheck BG every 1 hour until> 90 mg/dL and then restart infusion in next Lower algorithm BG between 90 and 140 mg/dL (goal) Adjust the rate within the SAME algorithm BG between 141 and 180 mg/dL and decreased by 30 mg/dL or more Adjust the rate within the SAME algorithm BG between 141 and 180 mg/dL and did not decrease by at least 30 mg/dL Adjust the rate to the next HIGHER algorithm BG > 180 mg/dL and decreased by 60 mg/dL or more Adjust the rate within the SAME algorithm BG > 180 mg/dL and did not decrease by at least 60 mg/dL Adjust the rate to the next HIGHER algorithm Blood Glucose (mg/dl) Scale 1 (ml/hr) Scale 2 (ml/hr) Scale 3 (ml/hr) Scale 4 (ml/hr) Scale 5 (ml/hr) Scale 6 (ml/hr) Scale 7 (ml/hr) Scale 8 (ml/hr) ≥400 3 4 5 6 7 8 10 11 320-399 2.5 3.5 4 5 6 6 8 9 250-319 2 3 3 4 5 5 6 7 210-249 1.5 2.5 2.5 3 4 4 4 5 180-209 1 2 2 2 3 3 3 4 140-179 1 1.5 1.5 1.5 2 2 2.5 3 110-139 0.5 1 1 1 1.5 1.5 2 2 90-109 0.5 0.5 0.5 1 1 1 1.5 1.5 <90 Stop IV insulin infusion and inform doctor
  • 12. Rocuronium Bromide (Esmeron) Strength 10 mg/ml amp=5ml Compatibility D5W, NS. Dilution 250 mg (5 amp) *50 ml Concentration 5 mg / ml Dose Initial dose (0.6 mg/kg) Maintenance infusion: 0.3 to 0.6 mg/kg/hour Stability  24 hr Dose (mg) WT(kg) 30 40 50 60 70 80 90 100 Infusion Rates ml/ hr 0.3 1.8 2.4 3 3.6 4.2 4.8 5.4 6 0.35 2.1 2.8 3.5 4.2 4.9 5.6 6.3 7 0.4 2.4 3.2 4 4.8 5.6 6.4 7.2 8 0.45 2.7 3.6 4.5 5.4 6.3 7.2 8.1 9 0.5 3 4 5 6 7 8 9 10 0.55 3.3 4.4 5.5 6.6 7.7 8.8 9.9 11 0.6 3.6 4.8 6 7.2 8.4 9.6 10.8 12